Edition:
United States

Novartis AG (NVS.N)

NVS.N on New York Stock Exchange

83.22USD
20 Nov 2017
Change (% chg)

$-0.76 (-0.90%)
Prev Close
$83.98
Open
$84.00
Day's High
$84.04
Day's Low
$83.21
Volume
338,906
Avg. Vol
277,028
52-wk High
$86.90
52-wk Low
$66.93

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 0.74
Market Cap(Mil.): $219,321.00
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.72
Yield (%): 3.24

Financials

  Industry Sector
P/E (TTM): -- 31.35 15.79
EPS (TTM): -- -- --
ROI: -- 15.11 12.01
ROE: -- 16.52 15.91

BRIEF-Novartis's Tasigna wins additional EU approval

* Novartis drug Tasigna (nilotinib) secures eu approval for first and second-line treatment of ph+ cml-cp in children Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

1:18am EST

Pfizer, Novartis agree UK price cuts for new breast cancer drugs

LONDON Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain's state-funded health service.

Nov 15 2017

Pfizer, Novartis agree UK price cuts for new breast cancer drugs

LONDON, Nov 16 Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain's state-funded health service.

Nov 15 2017

Novartis launches heart drug counter-offensive

ZURICH Novartis plans to plow through doubts over its canakinumab drug by asking regulators this year to approve the medicine as a treatment for a group of heart attack survivors that the Swiss drugmaker says is most likely to benefit.

Nov 13 2017

Novartis launches heart drug counter-offensive

ZURICH, Nov 13 Novartis plans to plow through doubts over its canakinumab drug by asking regulators this year to approve the medicine as a treatment for a group of heart attack survivors that the Swiss drugmaker says is most likely to benefit.

Nov 13 2017

Swiss stocks - Factors to watch on Nov 13

ZURICH, Nov 13 The Swiss blue-chip SMI was seen opening 0.3 percent higher at 9,159 points on Monday, according to premarket indications by bank Julius Baer .

Nov 13 2017

German stocks - Factors to watch on November 13

BERLIN/FRANKFURT, Nov 13 The following are some of the factors that may move German stocks on Monday:

Nov 13 2017

Novartis posts eye drug data amid play for Eylea's turf

ZURICH Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.

Nov 10 2017

Novartis posts eye drug data amid play for Eylea's turf

ZURICH, Nov 10 Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.

Nov 10 2017

Regeneron third-quarter profit easily tops Street view on Eylea, Dupixent sales

Regeneron Pharmaceuticals Inc on Wednesday reported third-quarter profit that sailed past Wall Street estimates on the strength of increased demand for flagship eye treatment Eylea and its new eczema drug Dupixent, boosting its shares almost 7 percent.

Nov 08 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $137.93 -0.07
Pfizer Inc. (PFE.N) $35.35 -0.02
Merck & Co., Inc. (MRK.N) $54.10 -1.10
Roche Holding Ltd. (ROG.S) CHF243.60 +13.50
Roche Holding Ltd. (RO.S) CHF246.00 +12.70
Abbott Laboratories (ABT.N) $55.29 -0.27
Sanofi SA (SASY.PA) €75.75 --
AstraZeneca plc (AZN.L) 4,960.50 -14.50
GlaxoSmithKline plc (GSK.L) 1,313.50 +5.50
Eli Lilly and Co (LLY.N) $83.18 +0.29

Earnings vs. Estimates